Education
About Us
Working with TipRanks
Follow Us
Nuvation Bio (NUVB)
NYSE:NUVB
NUVB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.67 - $4.16
Previous CloseN/A
Volume977.37K
Average Volume (3M)2.00M
Market Cap
$665.01M
Enterprise Value$88.52M
Total Cash (Recent Filing)-$138.00K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.25
Next Earnings
May 20, 2025EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.17
Shares Outstanding336,566,530
10 Day Avg. Volume1,624,398
30 Day Avg. Volume2,000,982
Standard Deviation0.21
R-Squared0.11
Alpha-0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)306.68
Price to Cash Flow (P/CF)-5.30
P/FCF Ratio0.00
Enterprise Value/Market Cap0.13
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-398.74
Enterprise Value/Ebitda-0.16
Forecast
1Y Price Target
$10.50Price Target Upside432.99% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Nuvation Bio News
PremiumCompany Announcements
Nuvation Bio CEO Departs After Achieving Key Goals
PremiumCompany Announcements
Nuvation Bio’s Q3 2024 Highlights and Future Prospects---
Bulls Say, Bears Say
Bulls Say
Efficacy And Market PotentialTaletrectinib has shown superior efficacy with a median progression-free survival of 46 months in the 1L setting.
Regulatory ProgressNuvation announced that the FDA has accepted the company’s New Drug Application (NDA) for taletrectinib.
Bears Say
Approval And Commercial RisksRisks include the failure to obtain timely approval for pipeline candidates, particularly taletrectinib.
---
Ownership Overview
27.30% Insiders
12.47% Mutual Funds
20.18% Other Institutional Investors
31.19% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NUVB FAQ
What was Nuvation Bio’s price range in the past 12 months?
Nuvation Bio lowest stock price was $1.67 and its highest was $4.16 in the past 12 months.
What is Nuvation Bio’s market cap?
Nuvation Bio’s market cap is $665.01M.
When is Nuvation Bio’s upcoming earnings report date?
Nuvation Bio’s upcoming earnings report date is May 20, 2025 which is in 78 days.
How were Nuvation Bio’s earnings last quarter?
Currently, no data Available
Is Nuvation Bio overvalued?
According to Wall Street analysts Nuvation Bio’s price is currently Undervalued.
Does Nuvation Bio pay dividends?
Nuvation Bio does not currently pay dividends.
What is Nuvation Bio’s EPS estimate?
Nuvation Bio’s EPS estimate is -0.13.
How many shares outstanding does Nuvation Bio have?
Nuvation Bio has 336,566,530 shares outstanding.
What happened to Nuvation Bio’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Nuvation Bio?
Currently, no hedge funds are holding shares in NUVB
---
Nuvation Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.50 (432.99% Upside)
$10.50 (432.99% Upside)
Blogger Sentiment
Bullish
NUVB Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 208.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $162.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 3.4%
Last 30 Days ▼ 3.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
0.00%
12-Months-Change
Fundamentals
Return on Equity
-95.54%
Trailing 12-Months
Asset Growth
-9.40%
Trailing 12-Months
Company Description
Nuvation Bio
Panacea Acquisition Corp is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.
---
NUVB Stock 12 Month Forecast
Average Price Target
$10.50
▲(432.99% Upside)
Technical Analysis
Fate Therapeutics
―
Iovance Biotherapeutics
―
Blueprint Medicines
―
Crispr Therapeutics AG
―
Immatics
―
Best Analysts Covering NUVB
1 Year
1 Year Success Rate
5/14 ratings generated profit
1 Year Average Return
+0.34%
reiterated a buy rating 4 days ago
Copying Gregory Renza's trades and holding each position for 1 Year would result in 35.71% of your transactions generating a profit, with an average return of +0.34% per trade.
---